Clinical Efficacy Study of Tolvaptan on Patients with Autosomal Dominant Polycystic Kidney Disease

Clinical Efficacy Study of Tolvaptan on Patients with Autosomal Dominant Polycystic Kidney Disease - Efficacy Study of Tolvaptan

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015715

Enrollment

100

Registered

2014-11-25

Start date

2014-11-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autosomal Dominant Polycystic Kidney Disease

Interventions

Tolvaptan administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who started or will start tolvaptan treatment in our institute and gave or will give consent to participate to this study. 2)Patients who visited or will visit our institute, received or will receive clinical evaluations and gave or will give informed consent to use their clinical data.

Exclusion criteria

Exclusion criteria: 1)Patients who did not or will not give consent to participate to the study protocol. 2)Patients who is considered to be excluded by physicians.

Design outcomes

Primary

Measure	Time frame
Annual change rate of Total Kidney Volume (TKV slope; ml/year, % /year)	—

Secondary

Measure	Time frame
Annual change rate of eGFR (eGFR slope; ml/min/1.73m2 per year) which is estimated by creatinine and cystatin-C.	—

Countries

Japan

Contacts

Public ContactEiji Higashihara

Kyorin University School of Medicine ADPKD Research

ehigashi@ks.kyorin-u.ac.jp0422-49-7428

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026